Stocks News

LAST PRICE
302.7600
TODAY'S CHANGE (%)
Trending Down-2.2600 (-0.7409%)

Bid / Lots
302.6400/ 2
Ask / Lots
303.1500/ 4
Open / Previous Close
304.5500 / 305.0200
Day Range
Low 302.0100
High 305.5300
52 Week Range
Low 215.3200
High 329.7200
Volume
217,984
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Jun 5, 2024
- AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, from 4:00PM ET on Wednesday Jun 05, 2024 by Dow Jones
  4:00PM ET on Wednesday Jun 05, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
  
  PR Newswire
  
  THOUSAND OAKS, Calif., June 5, 2024
  
  THOUSAND OAKS, Calif., June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45(th) Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, June 10, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
- Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints, from 9:57AM ET on Wednesday Jun 05, 2024 by MT Newswires
  9:57AM ET on Wednesday Jun 05, 2024 by MT Newswires
  Companies Mentioned: AMGN
  09:57 AM EDT, 06/05/2024 (MT Newswires) -- Amgen (AMGN) said Wednesday its phase 3 clinical trial evaluating Uplizna as a treatment for immunoglobulin G4-related disease, an autoimmune condition, met its primary and key secondary endpoints. The comp...
- DJ Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD, from 9:28AM ET on Wednesday Jun 05, 2024 by Dow Jones
  9:28AM ET on Wednesday Jun 05, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  By Colin Kellaher
  
  Amgen on Wednesday said a late-stage study of its autoimmune drug Uplizna hit its key goals in the treatment of immunoglobulin G4-related disease, a chronic, immune-mediated disease known as IgG4-RD.
- AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA(R) (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD), from 9:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
  9:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA(R) (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
  
  PR Newswire
Jun 3, 2024
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE, from 4:00PM ET on Monday Jun 03, 2024 by Dow Jones
  4:00PM ET on Monday Jun 03, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
  
  PR Newswire
  
  THOUSAND OAKS, Calif., June 3, 2024
  
  THOUSAND OAKS, Calif., June 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m. ET on Thursday, June 6, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Ian Thompson, senior vice president, U.S. Business Operations at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Today
- Pfizer's Paxlovid Failed to Show Clear Benefits Among Long-COVID Patients in Stanford Study, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: PFE
Jun 6, 2024
- Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA, from 8:14AM ET on Thursday Jun 06, 2024 by MT Newswires
  8:14AM ET on Thursday Jun 06, 2024 by MT Newswires
  Companies Mentioned: GILD
Jun 5, 2024
- Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment, from 5:04PM ET on Wednesday Jun 05, 2024 by MT Newswires
  5:04PM ET on Wednesday Jun 05, 2024 by MT Newswires
  Companies Mentioned: PFE, RLAY
- Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial, from 4:46AM ET on Wednesday Jun 05, 2024 by MT Newswires
  4:46AM ET on Wednesday Jun 05, 2024 by MT Newswires
  Companies Mentioned: GILD
Jun 4, 2024
- Sector Update: Health Care Stocks Rise Late Afternoon, from 3:56PM ET on Tuesday Jun 04, 2024 by MT Newswires
  3:56PM ET on Tuesday Jun 04, 2024 by MT Newswires
  Companies Mentioned: GILD, ELV, NDRA, AMRN
- Sector Update: Health Care Stocks Rise Tuesday Afternoon, from 1:50PM ET on Tuesday Jun 04, 2024 by MT Newswires
  1:50PM ET on Tuesday Jun 04, 2024 by MT Newswires
  Companies Mentioned: GILD, SILO, AMRN
- Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit, from 11:05AM ET on Tuesday Jun 04, 2024 by MT Newswires
  11:05AM ET on Tuesday Jun 04, 2024 by MT Newswires
  Companies Mentioned: GILD
Jun 3, 2024
- Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma, from 12:09PM ET on Monday Jun 03, 2024 by MT Newswires
  12:09PM ET on Monday Jun 03, 2024 by MT Newswires
  Companies Mentioned: GILD
- Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints, from 8:37AM ET on Monday Jun 03, 2024 by MT Newswires
  8:37AM ET on Monday Jun 03, 2024 by MT Newswires
  Companies Mentioned: TAK, PFE
- Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise, from 4:26AM ET on Monday Jun 03, 2024 by MT Newswires
  4:26AM ET on Monday Jun 03, 2024 by MT Newswires
  Companies Mentioned: GILD, RCUS

Amgen Inc
NASDAQ:AMGNUnited States

Search Criteria

Jun 5, 2024

AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, from 4:00PM ET on Wednesday Jun 05, 2024 by Dow Jones

Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints, from 9:57AM ET on Wednesday Jun 05, 2024 by MT Newswires

DJ Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD, from 9:28AM ET on Wednesday Jun 05, 2024 by Dow Jones

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA(R) (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD), from 9:00AM ET on Wednesday Jun 05, 2024 by Dow Jones

Jun 3, 2024

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE, from 4:00PM ET on Monday Jun 03, 2024 by Dow Jones

Peers Headlines

Today

Pfizer's Paxlovid Failed to Show Clear Benefits Among Long-COVID Patients in Stanford Study, from 3 hours ago by MT Newswires

Jun 6, 2024

Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA, from 8:14AM ET on Thursday Jun 06, 2024 by MT Newswires

Jun 5, 2024

Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment, from 5:04PM ET on Wednesday Jun 05, 2024 by MT Newswires

Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial, from 4:46AM ET on Wednesday Jun 05, 2024 by MT Newswires

Jun 4, 2024

Sector Update: Health Care Stocks Rise Late Afternoon, from 3:56PM ET on Tuesday Jun 04, 2024 by MT Newswires

Sector Update: Health Care Stocks Rise Tuesday Afternoon, from 1:50PM ET on Tuesday Jun 04, 2024 by MT Newswires

Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit, from 11:05AM ET on Tuesday Jun 04, 2024 by MT Newswires

Jun 3, 2024

Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma, from 12:09PM ET on Monday Jun 03, 2024 by MT Newswires

Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints, from 8:37AM ET on Monday Jun 03, 2024 by MT Newswires

Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise, from 4:26AM ET on Monday Jun 03, 2024 by MT Newswires